Amicus Therapeutics, Inc.(link is external) (Nasdaq:FOLD), has received Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) for the novel topical medicine SD-101 for the treatment of epidermolysis bullosa (EB). The Rare Pediatric Disease designation for SD-101 covers the broad treatment of EB. In addition to the Rare Pediatric Disease designation, SD-101 has Orphan Drug designation and was one of the first treatments to receive the FDA’s Breakthrough Therapy designation.

The FDA grants Rare Pediatric Disease designation for diseases that primarily affect children ages 18 years or younger and fewer than 200,000 persons in the U.S. If a new drug application (NDA) for SD-101 is approved, Amicus is eligible to receive a priority review voucher that may be sold or transferred.

John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. stated, “This Rare Pediatric Disease designation is significant in its broad coverage for the treatment of EB, and adds to our previous Orphan Drug and Breakthrough Therapy designations for SD-101 from the FDA. We believe that these important designations highlight the urgent need for a treatment for this devastating rare disease. SD-101, which we are developing for all three major types of EB, was the first drug to enter Phase 3 development for EB, and has the potential to be the first FDA-approved therapy. SD-101 has the potential to provide meaningful clinical benefit to patients and their caregivers and we eagerly await the results of our Phase 3 study.”

Amicus is on track to report top-line data from the Phase 3 ESSENCE study of SD-101 during the third quarter of 2017. ESSENCE is a double-blind, placebo-controlled registration study that completed enrollment of more than 160 patients who have a documented diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB. To date, more than 95 percent of patients completing the 3-month primary treatment period have elected to continue in the open-label extension study.

About Epidermolysis Bullosa (EB)
EB(link is external) is a rare, genetic disorder that manifests as blistering or erosion of the skin, and, in some cases, the epithelial lining of other organs. EB is chronic, potentially disfiguring, and in some cases fatal. Patients with EB have painful wounds and blisters that can lead to infection and scarring. There are many genetic and symptomatic variations of EB, but all forms share the common symptom of fragile skin that blisters and tears, sometimes from the slightest friction or trauma. There is currently no approved treatment for EB. Current standard of care consists of pain management and the bandaging and cleaning of open wounds to prevent infection.

About Amicus Therapeutics 
Amicus Therapeutics(link is external) (Nasdaq:FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat(link is external) as a monotherapy for Fabry disease, SD-101(link is external) for epidermolysis bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.

5,161 thoughts on “Amicus Therapeutics Receives Rare Pediatric Disease Designation for SD-101 for Patients with Epidermolysis Bullosa”

  1. Violet says:

    I’m no longer sure where you are getting your information, but great topic.

    I needs to spend some time studying more or understanding more.
    Thanks for wonderful info I was searching for this information for my mission.

  2. Renate says:

    Hi, how are you? This post has been the very best thing I have actually read
    throughout the day.

  3. Keri says:

    Hi there, I found your honestly in this post rejuvenating.
    Anticipating learning more from you.

  4. panoseuraa says:

    Hi, I hope you are well. I truly enjoyed reading this blog.
    I eagerly anticipate your next post.

  5. Willis says:

    Hi, I hope you are well. I actually enjoyed reading this blog site.
    I eagerly anticipate your next post.

  6. The other day, while I was at work, my cousin stole my
    apple ipad and tested to see if it can survive a forty foot
    drop, just so she can be a youtube sensation. My iPad is now broken and she has 83 views.

    I know this is entirely off topic but I had to share it with someone!

  7. It’s in reality a great and useful piece of information. I’m happy that you just shared this helpful info with us.

    Please keep us informed like this. Thank you for sharing.

  8. Pretty component of content. I just stumbled upon your site and in accession capital to say that I get in fact loved
    account your blog posts. Any way I’ll be subscribing on your feeds and even I
    achievement you get admission to consistently quickly.

  9. Definitely consider that which you said. Your favourite reason seemed to be on the internet the easiest factor to take into account of.
    I say to you, I certainly get annoyed even as other folks
    think about concerns that they just don’t understand about.

    You managed to hit the nail upon the highest and also outlined out the entire thing with no need side effect , people can take a signal.
    Will likely be again to get more. Thank you

  10. Hey there! I’ve been following your blog for a long time now and finally got the bravery to go ahead and
    give you a shout out from Porter Texas! Just wanted to say keep up the excellent work!

  11. Hi there would you mind sharing which blog platform you’re
    working with? I’m going to start my own blog in the near future but I’m
    having a hard time deciding between BlogEngine/Wordpress/B2evolution and Drupal.
    The reason I ask is because your design seems different then most blogs and I’m looking for something
    completely unique. P.S My apologies for
    getting off-topic but I had to ask!

  12. No matter if some one searches for his necessary thing, so he/she wants to be available that in detail, therefore that thing is maintained over

  13. Wonderful article! This is the type of info that should be shared across the web.
    Shame on Google for not positioning this publish
    higher! Come on over and discuss with my web site .
    Thanks =)

  14. Right away I am going away to do my breakfast, once having my breakfast coming over again to read more news.

  15. Wonderful blog! I found it while searching on Yahoo News.
    Do you have any suggestions on how to get listed in Yahoo News?
    I’ve been trying for a while but I never seem to get there!

  16. Fabulous, what a blog it is! This webpage presents useful facts
    to us, keep it up.

  17. I’ll right away grab your rss as I can not to find your email subscription hyperlink
    or e-newsletter service. Do you’ve any? Kindly permit me know in order that I could subscribe.

  18. It’s a shame you don’t have a donate button! I’d without a
    doubt donate to this brilliant blog! I suppose for now i’ll
    settle for book-marking and adding your RSS feed to my Google account.
    I look forward to new updates and will talk about this site
    with my Facebook group. Chat soon!

  19. Jay says:

    Hello there! I could have sworn I’ve been to your blog before but
    after looking at some of the posts I realized it’s new
    to me. Regardless, I’m certainly happy I came across it and I’ll be bookmarking it and checking
    back regularly!

  20. seksiseuraa says:

    Pretty nice post. I just stumbled upon your weblog and wished to say that I’ve really enjoyed browsing your blog posts.

    After all I will be subscribing to your rss feed and I hope you
    write again soon!

  21. Catharine says:

    You actually make it seem so easy with your
    presentation but I find this topic to be actually something that I
    think I would never understand. It seems too complicated and very
    broad for me. I am looking forward for your next post, I’ll try to get the hang
    of it!

  22. Appreciating the dedication you put into your blog and detailed information you present.
    It’s good to come across a blog every once in a while that
    isn’t the same outdated rehashed information. Excellent read!
    I’ve bookmarked your site and I’m adding your RSS feeds to my Google account.

  23. If some one needs expert view concerning blogging after that i recommend him/her to
    pay a quick visit this webpage, Keep up the
    nice work.

  24. quest bars says:

    My coder is trying to persuade me to move to .net from PHP.
    I have always disliked the idea because of the costs.
    But he’s tryiong none the less. I’ve been using Movable-type on a variety of websites for about a year
    and am concerned about switching to another platform.
    I have heard excellent things about Is there a way I
    can transfer all my wordpress content into it?
    Any kind of help would be really appreciated!

  25. Hi there everyone, it’s my first visit at this web page, and piece of writing is really fruitful in support of me, keep up posting such articles or reviews.